X0306 4 2021-02-22 0 0001549595 Nurix Therapeutics, Inc. NRIX 0001817217 van Houte Hans C/O NURIX THERAPEUTICS, INC. 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 0 1 0 0 Chief Financial Officer Common Stock 2021-02-22 4 M 0 1417 0.84 A 1417 D Common Stock 2021-02-22 4 M 0 3913 1.20 A 5330 D Common Stock 2021-02-22 4 S 0 5330 39.9323 D 0 D Employee Stock Option (right to buy) 0.84 2021-02-22 4 M 0 1417 0.00 D 2026-04-26 Common Stock 1417 68333 D Employee Stock Option (right to buy) 1.20 2021-02-22 4 M 0 3913 0.00 D 2028-03-01 Common Stock 3913 29420 D This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Represents the weighted average sale price. The lowest price at which shares were sold was $39.90 and the highest price at which shares were sold was $40.03. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. The option is fully vested. The stock option vests as to 1/48 of the total shares monthly beginning February 2, 2018 until the option is fully vested on January 2, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. /s/ Christine Ring, as Attorney-in-Fact for Hans van Houte 2021-02-23